Sunkel Benjamin D, Stanton Benjamin Z
Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, Columbus, OH 43205, USA.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43205, USA.
iScience. 2021 Sep 15;24(10):103132. doi: 10.1016/j.isci.2021.103132. eCollection 2021 Oct 22.
Transcription factors (TFs) are essential mediators of epigenetic regulation and modifiers of penetrance. Studies from the past decades have revealed a sub-class of TF that is capable of remodeling closed chromatin states through targeting nucleosomal motifs. This pioneer factor (PF) class of chromatin remodeler is ATP independent in its roles in epigenetic initiation, with nucleosome-motif recognition and association with repressive chromatin regions. Increasing evidence suggests that the fundamental properties of PFs can be coopted in human cancers. We explore the role of PFs in the larger context of tissue-specific epigenetic regulation. Moreover, we highlight an emerging class of chimeric PF derived from translocation partners in human disease and PFs associated with rare tumors. In the age of site-directed genome editing and targeted protein degradation, increasing our understanding of PFs will provide access to next-generation therapy for human disease driven from altered transcriptional circuitry.
转录因子(TFs)是表观遗传调控的重要介质和外显率的调节因子。过去几十年的研究揭示了一类转录因子,它们能够通过靶向核小体基序重塑封闭的染色质状态。这类先驱因子(PF)在表观遗传起始过程中发挥作用时不依赖ATP,具有核小体基序识别以及与抑制性染色质区域结合的能力。越来越多的证据表明,先驱因子的基本特性可在人类癌症中被利用。我们在组织特异性表观遗传调控的更大背景下探讨先驱因子的作用。此外,我们重点介绍了一类在人类疾病中由易位伙伴产生的嵌合先驱因子以及与罕见肿瘤相关的先驱因子。在定点基因组编辑和靶向蛋白质降解的时代,加深对先驱因子的理解将为因转录回路改变而引发的人类疾病提供下一代治疗方法。